17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of the molecular chaperone heat shock protein 90, results in cell type-specific inhibition of proliferation of leukemic cells. GTP14564 is a tyrosine kinase inhibitor actively against FLT3. The current study evaluated the single and combined effects of 17-AAG and GTP14564, and the role of FLT3 in their inhibitory effects. The importance of FLT3 mutations was demonstrated using small interfering RNA (siRNA) targeted to FLT3. Similar to FLT3 siRNA, GTP14564 inhibited FLT3 internal tandem duplication (ITD) cells (MV4;11) and FLT3 amplified wild-type cells (SEMK2-M1), but not wild-type FLT3 cells (RS4;11). However, when RS4;11 cells were stimulated with FLT3-ligand, phosphorylation of STAT5 and GTP14564 inhibition were observed. Responses to GTP14564 in all cell types were directly related to the level of STAT5 phosphorylation in the cells. We observed synergistic effects of combined 17-AAG and GTP14564 in cell lines with FLT3-ITD and amplified wild-type FLT3. Combined treatment with 17-AAG and GTP14564 reduced the levels of p-FLT3 and p-STAT5, enhanced G0/G1 arrest and apoptosis in FLT3-ITD and amplified wild-type FLT3. The combination of 17-AAG with FLT3 kinase inhibitors can enhance targeted therapy in leukemias with FLT3 mutations, such as MLL fusion gene leukemias.
Introduction
FLT3 is a receptor tyrosine kinase that is expressed in the wildtype form in many human leukemias including acute myeloid leukemia (AML) and B-lineage acute lymphoblastic leukemia; also, FLT3 is constitutively activated by an internal tandem duplication (ITD) mutation within the juxtramembrane domain or tyrosine kinase domain in 20-30% of patients with AML. [1] [2] [3] [4] [5] Wild-type FLT3 and especially activating mutations of FLT3 are likely to be useful molecular targets for therapy. 6, 7 Several FLT3 kinase inhibitors are currently in development. [3] [4] [5] [6] [7] [8] [9] [10] [11] A novel FLT3 kinase inhibitor, GTP14564, has recently been described. 12 GTP14564 strongly inhibited cell proliferation of IL3-independent murine pro-B Ba/F3 cells that express ITD-FLT3 and less effectively inhibited cell proliferation of FLT3 ligand (FL) dependent Ba/F3 cells expressing wild-type FLT3. 12 FLT3 may potentially be targeted for therapy using other agents. Heat-shock protein 90 (Hsp90) was a molecular chaperone for FLT3 in previous studies by our group and others. 13, 14 We found that both wild-type FLT3 and ITD-FLT3 are client proteins of Hsp90.
14 Hsp90 is also a molecular chaperone of other protein kinases, such as, RAF, AKT and Erb2. 15 Hsp90 inhibitors have been found to be effective in vitro in combination with several chemotherapeutic agents. [16] [17] [18] [19] [20] One specific inhibitor of Hsp90, 17-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin, has attracted much interest because of its potential effectiveness in vivo. [17] [18] [19] [20] 17-AAG is now in clinical trials in several human solid tumors. Our previous studies demonstrated that 17-AAG inhibited human leukemia cells with either wild-type FLT3 or ITD-FLT3.
14 Thus, 17-AAG is potentially clinically useful as a single agent for FLT3 expressing leukemias and clinical trials in leukemias are now underway.
Previous studies showed that (1) many FLT3 inhibitors, including CEP701, CT53518, PKC412, SU5416, SU5614, SU11248 and GTP14564, inhibited leukemia cells with mutated FLT3; [3] [4] [5] [6] [7] [8] [9] [10] [11] (2) PKC412 also inhibited leukemia cells with amplified wild-type FLT3; 1 and (3) recently the combination of 17-AAG with PKC412 was reported to have synergistic cytotoxic effects against leukemia cells with mutated FLT3. 21 In this study, we examined the effects of combination of 17-AAG with the novel FLT3 inhibitor, GTP14564, in cell lines with differing FLT3 abnormalities. To evaluate in depth the role of FLT3 in sensitivity to these drugs, we utilized knockdown of FLT3 expression using small interfering RNA (siRNA) and detected the effects of 17-AAG and GTP14564 alone and in combination on FLT3 downstream signal transduction kinases. We studied the role of the three major pathways (MAPK, AKT/ PKB and STAT) in these effects. We also conducted cell cycle and apoptosis analysis in these studies. Our results demonstrate that GTP14564 and 17-AAG are synergistic in their activity against leukemia cells that express mutated FLT3 and amplified wild-type FLT3. Our results provide evidence that the mechanisms of cell inhibition by the FLT3 inhibitor, GTP14564 and the Hsp90 inhibitor, 17-AAG are not identical and that the STAT5 signal transduction pathway plays a key role in the synergistic effects. The studies also provide preclinical data suggesting the value of clinical studies that combine an FLT3 inhibitor and an Hsp90 inhibitor.
Materials and methods

Reagents
17-AAG was provided by the Developmental Therapeutics Program of the National Cancer Institute. GTP14564 from SPECS and BioSPECS BV, Inc. (Rijswijk, Netherlands) is available under the name 1-phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden. Both drugs were dissolved in DMSO to a 10 mM stock solution. 'SMARTpool' for human FLT3, combination of four synthetic siRNA duplexes each of which was designed to reduce mRNA for human FLT3 and nonsilencing negative control siRNA were obtained from Dharmacon (Lafayette, CO, USA).
Cell culture and cell proliferation assay
Human leukemia cell lines, MV4;11, MOLM-13, SEMK2-M1 and RS4;11, were described previously.
14 MV 4;11 and MOLM-13 have previously been found to have ITD-FLT3 mutations, while SEMK2-M1 has amplified wild-type FLT3 and RS4;11 has wild-type FLT3 as shown in Table 1 . The cell lines were maintained in RPMI 1640 medium containing 10% FBS. For cell proliferation assays using the MTT method, cells seeded in replicates of six at a density of 1 Â 10 5 cells/ml in 96-well plates in the presence or absence of various concentrations of 17-AAG and GTP14564. Plates were incubated for indicated hours at 371C, 5% CO 2 , and proliferation was measured using Cell Titer 96 Aqueous non-radioactive cell proliferation assay (Promega, Madison, WI). Results are reported as means7s.e.m. for each point on the curve.
Transfection with siRNA
The cells were washed twice and resuspended in Opti-MEM medium (Invitrogen, CA, USA). Five million cells were then mixed with 10 mg of siRNA duplexes. Electroporation was performed using a BTX Electro Square Porator T820 (BTX, Holliston, MA, USA) with one pulse at 240 V. After electroporation, cells were immediately mixed with RPMI 1640 medium containing 10% FBS. Cell growth was calculated with the viable cell numbers detected by Trypan blue exclusion test.
Western blotting
Cells were lysed by sample buffer (62.5 mM Tris (pH 7.4), 2% SDS, 10% glycerol and the protease inhibitor 'Complete Mini' (Roche, Indianapolis, IA, USA)), and the cell lysate was clarified by centrifugation. About, 20 mg of cell lysate of each sample were electrophoresed by 12% SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted with different antibodies. Antibodies were purchased as follows: Hsp90 and Hsp70 from BD PharMingen (San Diego, CA, USA); FLT3, STAT5 and poly(ADP-ribose) polymerase (PARP) from Santa Cruz Biotechnologies, Inc. (Santa Cruz, CA, USA); p-FLT3, AKT, p-AKT, ERK1/2 and p-ERK1/2 from Cell Signaling Technology (Beverly, MA, USA); p-STAT5 from Upstate Biotechnology, Inc. (Lake Placid, NY, USA); actin from Sigma (St Louis, MI, USA). For detection, the blots were incubated with horseradish peroxidase-conjugated anti-IgG antibody (Promega, Madison, WI, USA) and developed using the ECL detection system (Amersham Pharmacia Biotech, Arlington Heights, IL, USA). The densitometric analysis was performed using a Molecular Analyst (Bio-Rad, Hercules, CA, USA).
Analysis of combined effects of drugs
Each of the cell lines was simultaneously exposed to 17-AAG and GTP 14564 for 72 h and inhibition of cell proliferation was determined by Cell Titer 96 aqueous nonradioactive cell proliferation assay. To calculate combined drug effects, the combination index (CI) method was used. The CI values were determined at different effect levels of growth inhibition as a quantitative measure of the degree of drug interaction using the computer software CalcuSyn (BioSoft, Ferguson, MO, USA). CIo1, CI ¼ 1 and CI41 indicate synergism, additive effect and antagonism, respectively. Combined drugs were used at fixed molar ratios. The drug doses that produced about 50% of growth inhibition in single drug experiments were chosen to determine an appropriate fixed molar ratio of two combined drugs.
Statistical analysis
Significant differences between values obtained in a population of cells treated with different experimental conditions were determined using the Student's t-test. Ps of o0.05 were assigned for significance.
Cell cycle analysis
One million cells were suspended in 1 ml solution containing 50 mg/ml propidium iodide (PI), 0.1% sodium citrate and 0.1% Table 1 Inhibition of proliferation of leukemia cell lines by 17-AAG and GTP14564 correlates with mutation/expression of FLT3 ITD; FLT3 internal tandem duplication mutation.
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Triton X-100. The PI stained samples were analyzed within 24 h. Cell cycle distribution and apoptosis were determined by the analysis of nuclear DNA content using CellQuest-Pro software (Becton Dickinson, Mountain View, CA, USA).
Results
Correlation between FLT3 mutation/expression and differential sensitivity to 17-AAG and GTP14564
First, we examined 16 human leukemia cell lines for expression of FLT3 and inhibition of cell growth by 17-AAG and GTP14564. Results are shown in Table 1 . Inhibition by 17-AAG as reported in our previous study demonstrates greatest sensitivity of cells with mutated FLT3 and least sensitivity of cells that lack FLT3. 14 The IC 50 of GTP14564 after 72 h of culture in media containing serum was determined using the same panel of the cell lines. Cell lines expressing ITD-FLT3 had the greatest sensitivity to both 17-AAG and GTP14564. One line that expressed wild-type FLT3, SEMK2-M1, had intermediate sensitivity to both 17-AAG and GTP14564; it is interesting that SEMK2-M1 has FLT3 gene amplification and expresses a very high level of FLT3 protein as reported previously. 6 The other cell lines expressing wild-type FLT3 expression showed the next level of sensitivity to 17-AAG but were very resistant to GTP14564 under optimal growth conditions used. Cell lines that were FLT3 negative were very resistant to both 17-AAG and GTP14564.
FLT3 siRNA inhibits proliferation of mutant FLT3 and amplified wild type FLT3 but not nonamplified wild-type FLT3 expressing cells
To evaluate the role of wild-type or mutated FLT3 in leukemia cells, we performed multiple experiments using siRNA for FLT3. As described in Materials and methods, we transfected a pool of siRNAs for FLT3 into wild-type FLT3 (RS4;11), amplified wild type FLT3 (SEMK2-M1) and ITD-FLT3 (MV4;11) cell lines using electroporation. The efficiency of transfection was analyzed by a flow cytometer to detect FITC-conjugated siRNA and resulted in equivalent (84-89%) efficiency in all three cell lines. We analyzed FLT3 protein expression at 0, 24, 48 and 72 h after transfection by Western blotting and a representative experiment is shown in Figure 1A . The values shown in Figure 1a reflect the portion of FLT3 expression remaining after siRNA transfection. FLT3 siRNAs dramatically reduced FLT3 protein in all the cell lines (RS4;11, SEMK2-M1, and MV4;11) after 24 h transfection. The FLT3 expression gradually increased after 48 and 72 h in SEMK2-M1 and MV4;11 cells.
Having demonstrated that siRNA is capable of reducing FLT3 levels in the three cell lines, we next evaluated the effects of reduced FLT3 on cell proliferation. Results are shown in Figure 1B . RS4;11 cells treated with FLT3 siRNA showed no difference in cell proliferation from control siRNA. In contrast, FLT3 siRNA-treated SEMK2-M1 cells showed mild growth inhibition, while FLT3 siRNA-treated MV4;11 cells demonstrated marked growth inhibition. Since 17-AAG inhibits mutiple targets in signal transduction pathway through Hsp90, an understanding of the combination of inhibition of 17-AAG targets and inhibition of FLT3 is important. The combination effects of 17-AAG and FLT3 siRNA in three cell lines are shown in Figure 1C . SEMK2-M1 and MV4;11 cells show synergistic effects while RS4;11 cells show an additive effect. These results demonstrate the dependence of cells with FLT3 mutation or amplification on the expression of the FLT3 mutation and the synergistic combination effect of 17-AAG and FLT3 inhibitor in cell lines with FLT3 mutation or amplification. In support of this conclusion are the results of GTP14564 in the same cell lines. The magnitude of inhibition is similar to the results with GTP14564 shown in 14 GTP14564 was reported to inhibit phosphorylation of ITD-FLT3 and the downstream target Stat5. 12 Here we compared the effects of 17-AAG and GTP14564 on the levels of phosphorylated forms and total amount of Hsp90 client kinases and other downstream targets in RS4;11, SEMK2-M1 and MV4;11 leukemia cells. MV4;11, SEMK2-M1 and RS4;11 cells were exposed to 100, 1000 and 1000 nM 17-AAG, respectively, for 24, 48 and 72 h. Figure 2 shows that 17-AAG reduced the total amount of FLT3 and AKT, induced Hsp70 and did not change the total ERK1/2 and STAT5 in all three cell lines. The total Hsp90 was not changed in MV4;11 and SEMK2-M1, but increased in RS4;11 cells. As shown in Figure 2 , apoptosis determined by cleaved PARP was induced in MV4;11 and SEMK2-M1, but not in RS4;11 cells. Phosphorylation of AKT and ERK1/2 was inhibited in MV4;11, SEMK2-M1 and RS4;11 cells. Also, p-FLT3 was inhibited in both MV4;11 and SEMK2-M1, while p-STAT5 was inhibited in MV4;11 but not in SEMK2-M1 cells. p-STAT5 was not detected in RS4;11 cells grown in the absence of FLT3-ligand (Figures 2 and 3 ) although p-STAT5 was found in cells grown in the medium with FLT3-ligand ( Figure 4d) .
Next, we determined the effect of GTP14564 on signal transduction kinases in different cell lines. MV4;11, SEMK2-M1 and RS4;11 cells were exposed to 300, 2000 and 2500 nM GTP14564, respectively, for 24, 48 and 72 h. As shown in Figure 3 , GTP14564 had no effect on the total amounts of FLT3, AKT, ERK1/2, STAT5, Hsp90 and Hsp70, but p-AKT and p-ERK1/2 were reduced in all three cell lines. p-FLT3 and p-STAT5 are reduced in both MV4;11 and SEMK2-M1 cells. Apoptosis was induced in both MV4;11 and SEMK2-M1 but not in RS4;11 cells following incubation with GTP14564.
Previous studies have demonstrated conflicting results on whether STAT5 is a downstream target of FLT3. Some studies suggested that STAT5 is an important target of constitutively active FLT3 mutants, but not of the ligand-stimulated wild-type FLT3. 22, 23 Other studies suggested that STAT5 is a downstream target for both constitutively active FLT3 mutants and the ligandstimulated wild-type FLT3. 12, 24, 25 In this study we show that phosphorylation of STAT5 was inhibited by GTP14564 in SEMK2-M1 cells, in which the amplified wild type FLT3 is highly phosphorylated (Figure 3) . The basal phosphorylation and enhanced phosphorylation of STAT5 induced by FLT3-ligand were reduced by GTP14564 treatment (Figure 4a) , and GTP14564 abolished FLT3-ligand induced proliferation of SEMK2-M1 cells (Figure 4b ). In RS4;11
Synergistic effects of GTP14564 and 17-AAG Q Yao et al cells (wild-type FLT3), the phosphorylation of STAT5 was observed only if cells were stimulated with FLT3-ligand and this phosphorylation was reduced by GTP14564 (Figure 4c ). Also in cell proliferation experiments we observed that GTP14564 abolished FLT3-ligand-induced proliferation of RS4;11 cells (Figure 4d) . Therefore, we conclude that STAT5 is an important down-stream target for ITD-FLT3 and FLT3-ligand stimulated wild type FLT3. The FLT3 inhibitor GTP14564 inhibits STAT5 phosphorylation in leukemia cells with both wild type and mutated FLT3.
17-AAG and GTP14564 are synergistic in the inhibition of cell proliferation of cell lines expressing ITD-FLT3 and amplified wild-type FLT3
To evaluate the combined effects of 17-AAG and GTP14564, we used MOLM-13 and MV4;11 as cell lines that expressed ITD-FLT3 and were very sensitive to both 17-AAG and GTP14564. SEMK2-M1, the cell line that expressed amplified wild-type FLT3, had an intermediate sensitivity to both 17-AAG and GTP14564. RS4;11 expresses wild-type FLT3 and has We evaluated the combined effect of 17-AAG and GTP14564 on MOLM-13, MV4;11, SEMK2-M1 and RS4;11. Each of the cell lines were exposed to varying concentrations of 17-AAG and GTP14564 at a fixed molar ratio for 72 h and inhibition of cell proliferation was determined. Combination indexes were plotted against fractional effects as described in Materials and methods. Combination index below 1 represents synergistic effects. As seen in Figure 5 , 17-AAG and GTP14564 synergistically inhibited cell proliferation of SEMK2-M1, MOLM-13 and MV4;11 cells. However, no synergism was observed in RS4;11 cells. In summary, synergism with combination of 17-AAG and GTP14564 was observed in cell lines which showed sensitivity to both drugs as single agents and the degree of synergism was related to the FLT3 status of the cells.
17-AAG and GTP14564 alone and in combination induce cell cycle G0/G1 arrest and apoptosis in MV4;11 and SEMK2-M1 cells
Next, we determined the effect of 17-AAG and GTP14564 alone and in combination on cell cycle and apoptosis of RS4;11, SEMK2-M1 and MV4;11 cells. In MV4;11 and SEMK2-M1 cells, after treatment with 17-AAG and GTP14564 alone for 48 h, a high percentage of cells was arrested in G0/G1 phase and o2N apoptotic portion cells were increased. The cotreatment of 17-AAG and GTP14564 induced more cells to accumulate in G0/G1 phase and more o2N cells than those cells treated with 17-AAG or GTP14564 used alone. The increased o2N apoptotic cells were associated with the increased cleavage of Figure 3 Effects of GTP14564 on total levels and phosphorylation status of signal transduction kinases of MV4;11, SEMK2-M1 and RS4;11 cells. Western blot analysis of Hsp90, Hsp70, FLT3, p-FLT3, AKT, p-AKT, ERK1/2, p-ERK1/2, STAT5, p-STAT5 and PARP in the cell lysates from MV4;11, SEMK2-M1 and RS4;11 cells, after treatment of GTP14564 at 0, 24, 48 and 72 h. The level of actin served as the loading control. MV4;11, SEMK2-M1, and RS4;11 cells were treated with 300, 2000, and 2500 nM GTP14564, respectively. 17-AAG downregulates total amount or phosphorylation status of signal transduction kinases of MV4;11, SEMK2-M1 and RS4;11 cells. Western blot analysis of Hsp90, Hsp70, FLT3, p-FLT3, AKT, p-AKT, ERK1/2, p-ERK1/2, STAT5, p-STAT5 and PARP in the cell lysates from MV4;11, SEMK2-M1 and RS4;11 cells after treatment of 17-AAG at 0, 24, 48 and 72 h. The level of actin served as the loading control. MV4;11, SEMK2-M1, and RS4;11 cells were treated with 100, 1000, and 1000 nM 17-AAG, respectively. Table 2 . In RS4;11 cells, 17-AAG alone induced more cells into G0/G1 arrest while GTP14564 had no effect on cell cycle. The cotreatment of 17-AAG and GTP14564 increased cells arrested in G0/G1 phase as 17-AAG alone. The portion of o2N cells with the treatments of the combination of 17-AAG and GTP14564 and each agent alone, was not significantly different from control cells.
Synergistic effects of GTP14564 and 17-AAG
Cotreatment with 17-AAG and GTP14564 reduced p-STAT5 and p-FLT3 in MV4;11 and SEMK2-M1 cells Finally, we tested whether the combination of 17-AAG and GTP14564 would demonstrate enhanced effects on signal transduction kinases when compared with either agent alone. As shown in Figure 6 , Hsp90 was not significantly altered by the combination of the two agents. Hsp70 was increased by 17-AAG but the addition of GTP14564 did not show enhanced response. The combination of the two agents increased the effects of each agent alone in the PARP apoptosis assay in MV4;11 and SEMK2 but not in RS4;11 cells. Total FLT3 Figure 5 Combination effects of 17-AAG and GTP14564 in human leukemia cell lines. The median effects of drug combination based on the results of MTT assays for RS4;11, SEMK2-M1, MOLM-13 and MV4;11 are shown. All cell lines treated with combinations of 17-AAG and GTP14564 added simultaneously at a fixed molar ratio (1 : 1).
Figure 6
Combinations of 17-AAG and GTP14564 downregulate p-FLT3, p-STAT5, p-AKT, p-ERK1/2, and induce the increased PARP cleavage, than either agent alone. Western blot analysis of Hsp90, Hsp70, FLT3, p-FLT3, AKT, p-AKT, ERK1/2, p-ERK1/2, STAT5, p-STAT5 and PARP in the cell lysates from MV4;11, SEMK2-M1 and RS4;11 cells, after treatment of 17-AAG and GTP14564 alone and in combination for 24 h is shown. MV4;11 cells were treated with 100 nM 17-AAG and/or 300 nM GTP14564, SEMK2-M1 with 1000 nM 17-AAG and/or 2000 nM GTP14564, and RS4;11 with 1000 nM 17-AAG and/or 2500 nM GTP14564. [3] [4] [5] [6] [7] [8] [9] [10] [11] The present data with GTP14564 in human leukemia combined with the previous reported studies also showed differential effects depending on the FLT3 status. SEMK2-M1 is a unique leukemia cell line that expresses amplified wild-type FLT3. Previously, we participated in a study demonstrating that the FLT3 inhibitor, PKC412, inhibited cell proliferation in SEMK2-M1 but had minimal inhibition in RS4;11 cells that express nonamplified FLT3. 6 In these studies we used siRNA to specifically examine the role of FLT3 molecule in leukemias that express wild-type or mutated FLT3. siRNA utilizes double-stranded RNA complexes to target specific genes for silencing. A short synthetic duplex RNA is long enough to induce gene-specific silencing but short to evade host responses. 26 We used transient transfection with siRNA to knockdown FLT3 gene expression. Although the inhibition of FLT3 by siRNA was not complete, FLT3 siRNA inhibited cell proliferation in SEMK2-M1 and MV4;11 but not in RS4;11. These data support the conclusion that FLT3 plays a major role in cells with ITD-FLT3, an intermediate role in cells with amplified wild-type FLT3 and a less effective role in cells with nonamplified wild-type FLT3.
Our results show that either 17-AAG or GTP14564 alone significantly reduced the levels of p-FLT3, p-STAT5, p-AKT and p-ERK1/2 in SEMK2-M1 and MV4;11 cells, which have amplified wild-type FLT3 and mutated FLT3, respectively. As compared with either agent alone, combination of 17-AAG and GTP14564 produced more apoptosis and more decline in p-FLT3, p-STAT5, p-AKT and p-ERK1/2 levels. Significant downregulation in the genes downstream of STAT5 that promote cell proliferation and survival, coupled with the decline in the levels of p-AKT (PKB/AKT pathway), and p-ERK1/2 (MAPK-RAF-ERK1/2 pathway) may be responsible for the synergistic apoptotic effects after the treatment of the combination of 17-AAG and GTP14564.
In contrast to SEMK2-M1 and MV4;11 cells, RS4;11 cells, which have normal wild-type FLT3, are insensitive to GTP14564 when grown in the presence of serum but without FLT3-ligand. We found that RS4;11 cells had nondetectable levels of p-FLT3 and p-STAT5 unless FLT3-ligand was added. In the presence of FLT3-ligand, RS4;11 cells showed increased level of p-FLT3, p-STAT5 and growth inhibition effect by GTP14564.
FLT3 is consistently expressed in either the wild-type or mutated form in acute lymphoblastic leukemias with rearrangement of the MLL gene. 14, 27 FLT3 is also mutated in many cases of human acute myeloid leukemia. Further studies of (1) incidence of FLT3 gene amplification, (2) correlation between FLT3 gene amplification or overexpression and (3) sensitivity to Hsp90 inhibitors and the FLT3 kinase inhibitors in primary leukemia samples will be important.
In conclusion, the in vitro synergistic activity between the Hsp90 inhibitor, 17-AAG and an FLT3 kinase inhibitor, GTP14564, provides useful leads for the design of trials that combine the two distinct classes of agents in vivo.
